Renoprotection with pituitary adenylate cyclase-activating polypeptide in cyclosporine A-induced nephrotoxicity

Journal of Investigative Medicine

Volumn 59, Issue 5, 2011, Pages 793-802

  Khan, Altaf M ^a   Li, Min ^a   Brant, Elizabeth ^a   Maderdrut, Jerome L ^a   Majid, Dewan S A ^a   Simon, Eric E ^b   Batuman, Vecihi ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antifibrotic; Apoptosis; Calcineurin inhibitor; Interstitial fibrosis; Neuropeptide; Tumor growth factor 1

Indexed keywords

CREATININE; CYCLOSPORIN A; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LACTATE DEHYDROGENASE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE; COLLAGEN TYPE 3; COLLAGEN TYPE 4; FIBRONECTIN; LAMININ; PROTECTIVE AGENT; PROTEIN ZO1; TRANSCRIPTION FACTOR E2A; TUMOR NECROSIS FACTOR; URINARY TRACT AGENT; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY CELL; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN SECRETION; RENAL PROTECTION; UPREGULATION; ANIMAL CELL; BRUSH BORDER; CELL DIFFERENTIATION; CELL STRUCTURE; CELL VIABILITY; CYTOKINE RELEASE; DNA FRAGMENTATION; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; EC50; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUBULE CELL; NECROSIS;

MURINAE; MUS;

EID: 85047687526     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31821452a2     Document Type: Article

References (45)

1. Mitrovic D, Popovic M, Glisic B, et al. Cyclosporine in the treatment of autoimmune disorders: a 10-year experience. Transplant Proc. 1998;30:4134. (Pubitemid 29013183)
2. Slattery C, Campbell E, McMorrow T, et al. Cyclosporine AYinduced renal fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol. 2005;167:395-407. (Pubitemid 43026096)
3. Li M, Hering-Smith KS, Simon EE, et al. Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol Dial Transplant. 2008;23:860-870. (Pubitemid 351767551)
4. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002;13:2600-2610.
5. Campistol JM, Inigo P, Larios S, et al. Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant. 2001;16(suppl 1):114-116. (Pubitemid 32492521)
6. Mascarell L, Truffa-Bachi P. New aspects of cyclosporin A mode of action: from gene silencing to gene up-regulation. Mini Rev Med Chem. 2003;3:205-214.
7. Janda E, Lehmann K, Killisch I, et al. RAS and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of RAS signaling pathways. J Cell Biol. 2002;156:299-313. (Pubitemid 34839911)
8. McMorrow T, Gaffney MM, Slattery C, et al. Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant. 2005;20:2215-2225. (Pubitemid 41510100)
9. Ng YY, Huang TP, Yang WC, et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int. 1998;54:864-876.
10. Radisky DC. Epithelial-mesenchymal transition. J Cell Sci. 2005;118:4325-4326.
11. Strutz FM. EMT and proteinuria as progression factors. Kidney Int. 2009;75:475-481.
12. Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61:283-357.
13. Szakaly P, Kiss P, Lubics A, et al. Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia/reperfusion. J Mol Neurosci. 2008;36:89-96.
14. Yang S, Yang J, Yang Z, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress. J Pharmacol Exp Ther. 2006;319:595-603.
15. Arimura A, Li M, Batuman V. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood. 2006;107:661-668. (Pubitemid 43076392)
16. Arimura A, Li M, Batuman V. Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38. Ann N Y Acad Sci. 2006;1070:1-4. (Pubitemid 44126621)
17. Li M, Cortez S, Nakamachi T, et al. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Cancer Res. 2006;66:8796-8803. (Pubitemid 44449197)
18. Li M, Maderdrut JL, Lertora JJ, et al. Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases. Regul Pept. 2008;145:24-32. (Pubitemid 350296365)
19. Li M, Balamuthusamy S, Khan AM, et al. Pituitary adenylate cyclase-activating polypeptide ameliorates cisplatin-induced acute kidney injury. Peptides. 2010;31:592-602.
20. Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol. 1999;162:1200-1205. (Pubitemid 29035454)
21. Khan AM, Li M, Balamuthusamy S, et al. Myeloma light chain-induced renal injury in mice. Nephron Exp Nephrol. 2010;116:e32-e41.
22. Khan MA, Islam MT, Castillo A, et al. Attenuation of renal excretory responses to Ang II during inhibition of superoxide dismutase in anesthetized rats. Am J Physiol Renal Physiol. 2010;298:F401-F407.
23. Li YL, Gao L, Zucker IH, et al. NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits. Cardiovasc Res. 2007;75:546-554. (Pubitemid 47080964)
24. Brown MR, Miller FJ Jr, Li WG, et al. Overexpression of human catalase inhibits proliferation and promotes apoptosis in vascular smooth muscle cells. Circ Res. 1999;85:524-533. (Pubitemid 29431953)
25. 2 in cultured endothelial cells. Arch Biochem Biophys. 1993;302:348-355. (Pubitemid 23212681)
26. Healy E, Dempsey M, Lally C, et al. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int. 1998;54:1955-1966. (Pubitemid 28533623)
27. MacLeod H, Goodwin DG, Damphousse C, et al. The DTH effector response and IL-2 are unaffected by cyclosporine A in autoimmune B6D2F1 mice. Cell Immunol. 2010;266:14-23.
28. Magnasco A, Rossi A, Catarsi P, et al. Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives. Curr Clin Pharmacol. 2008;3:166-173.
29. Ito H, Kasagi N, Shomori K, et al. Apoptosis in the human allografted kidney. Analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling. Transplantation. 1995;60:794-798.
30. Amore A, Emancipator SN, Cirina P, et al. Nitric oxide mediates cyclosporine-induced apoptosis in cultured renal cells. Kidney Int. 2000;57:1549-1559. (Pubitemid 30207913)
31. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol. 2001;159:1465-1475. (Pubitemid 32947976)
32. Kumar MS, Hendrix JA, Johnson AD, et al. Smooth muscle alpha-actin gene requires two E-boxes for proper expression in vivo and is a target of class I basic helix-loop-helix proteins. Circ Res. 2003;92:840-847. (Pubitemid 36542524)
33. Duymelinck C, Deng JT, Dauwe SE, et al. Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney Int. 1998;54:804-818. (Pubitemid 28397398)
34. Oleggini R, Musante L, Menoni S, et al. Characterization of a DNA binding site that mediates the stimulatory effect of cyclosporin-A on type III collagen expression in renal cells. Nephrol Dial Transplant. 2000;15:778-785. (Pubitemid 30311994)
35. Ceol M, Anglani F, Vianello D, et al. Direct effect of chronic cyclosporine treatment on collagen III mRNA expression and deposition in rat kidneys. Clin Nephrol. 2000;53(suppl 1):8-9. (Pubitemid 30204947)
36. Ye P, Habib SL, Ricono JM, et al. Fibronectin induces ureteric bud cells branching and cellular cord and tubule formation. Kidney Int. 2004;66:1356-1364. (Pubitemid 39298367)
37. Miner JH, Yurchenco PD. Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol. 2004;20:255-284. (Pubitemid 39488639)
38. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 2006;25:695-705.
39. Wang Z, Li Y, Sarkar FH. Signaling mechanism (s) of reactive oxygen species in epithelial-mesenchymal transition reminiscent of cancer stem cells in tumor progression. Curr Stem Cell Res Ther. 2010;5:74-80.
40. Calo L, Davis PA, Rigotti P, et al. EcNOS overexpression in CsA-treated renal transplant patients: implications for CsA-induced hypertension. Transplant Proc. 1998;30:2012-2013. (Pubitemid 28399407)
41. Marumo T, Nakaki T, Hishikawa K, et al. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension. 1995;25:764-768.
42. Djamali A, Vidyasagar A, Adulla M, et al. NOX-2 is a modulator of fibrogenesis in kidney allografts. Am J Transplant. 2009;9:74-82.
43. Navarro-Antolin J, Hernandez-Perera O, Lopez-Ongil S, et al. CsA and FK506 up-regulate eNOS expression: role of reactive oxygen species and AP-1. Kidney Int Suppl. 1998;68:S20-S24. (Pubitemid 28531770)
44. Vaudry D, Pamantung TF, Basille M, et al. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci. 2002;15:1451-1460. (Pubitemid 35477975)
45. Tan YV, Abad C, Lopez R, et al. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2009;106:2012-2017.